Sees FY24 gross margin 72%-74%. Sees FY24 operating expenses $80M-$84M. “We are energized by the strong momentum that was built in 2023 and look forward to continuing to both increase adoption and utilization of the RNS System and to expand access to RNS therapy in the large community of drug-resistant epilepsy patients while maintaining financial discipline,” concluded Becker.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NPCE:
- NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
- NPCE Earnings this Week: How Will it Perform?
- NeuroPace price target raised to $16 from $9 at Wells Fargo
- NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
- NeuroPace Announces Chief Legal Officer Irina Ridley’s Departure
